摘要
目的:探讨理肺汤加减联合孟鲁司特钠治疗支气管哮喘缓解期的临床疗效,及对肺功能、血清炎症因子的影响。方法:选取2017年1月~2020年1月惠州市中心人民医院收治的102例支气管哮喘缓解期患者,随机数字表法将其分为对照组与研究组,各51例。对照组采取孟鲁司特钠治疗,研究组在此基础上联合理肺汤加减。评估两组临床疗效和不良反应。比较两组治疗前后中医证候、肺功能及血清炎性因子。结果:研究组患者治疗总体有效率显著高于对照组(P<0.05)。治疗后两组患者中医证候积分及超敏C反应蛋白(hs-CRP)、白介素(IL-12)、白介素-17(IL-17)水平均显著低于治疗前(P<0.05),研究组患者中医证候积分、hs-CRP、IL-12和IL-17水平均显著低于对照组(P<0.05),治疗后两组患者白介素-10(IL-10)水平显著高于治疗前(P<0.05),研究组患者治疗后IL-10水平显著低于对照组(P<0.05)。研究组患者治疗后最大呼吸流量(PEF)、第1s用力呼吸容积(FEV1)、用力肺活量(FVC)和FEV/FVC等肺功能指标改变幅度显著大于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:理肺汤加减联合孟鲁司特钠治疗支气管哮喘缓解期均有较高疗效及安全性,可有效调节炎性因子水平,改善患者临床症状及肺功能。
Objective:To investigate the clinical effect of using Modified Lifei Decoction combined with Montelukast Sodium in the treatment of bronchial asthma in remission stage,and its influence on lung function and serum inflammatory factors.Methods:A total of 102 patients with bronchial asthma in remission stage admitted to our hospital from January 2017 to January 2020 were randomly divided into a controlled group and a study group,with 51 cases in each group.The controlled group was treated with Montelukast Sodium,and the study group was combined with Lifei Decoction on this basis.The clinical efficacy and adverse reactions of the two groups were evaluated.TCM syndromes,lung function and serum inflammatory factors were compared between the two groups before and after treatment.Results:The total effective rate of the study group was significantly higher than that of the controlled group(P<0.05).After treatment,TCM syndrome score and levels of hs-CRP,IL-12 and IL-17 in two groups were significantly lower than those before treatment(P<0.05).TCM syndrome score,hs-CRP,IL-12 and IL-17 levels in the study group were significantly lower than those in the controlled group(P<0.05).After treatment,the level of IL-10 in the two groups was significantly higher than that before treatment(P<0.05).The level of IL-10 in the study group was significantly lower than that in the controlled group(P<0.05).After treatment,the changes of PEF,FEV1,FVC and FEV1/FVC in the study group were significantly greater than those in the controlled group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Lifei Decoction combined with Montelukast Sodium in the treatment of bronchial asthma in remission stage has high efficacy and safety,can effectively regulate the level of inflammatory factors,improve the clinical symptoms and lung function of patients.
作者
孙惠华
钟启腾
钟韵畅
张剑辉
SUN Huihua;ZHONG Qiteng;ZHONG Yunchang(Department of Traditional Chinese Medicine of Huizhou Central People's Hospital,Huizhou Guangdong 516000,China)
出处
《四川中医》
2022年第4期55-58,共4页
Journal of Sichuan of Traditional Chinese Medicine
基金
广东省惠州市科技计划项目(编号:200519104577427)
关键词
理肺汤
孟鲁司特钠
支气管哮喘
缓解期
肺功能
血清炎症因子
Lifei Decoction
Montelukast Sodium
Bronchial asthma
Remission
Lung function
Serum inflammatory factors
作者简介
孙惠华,本科,副主任医师,主要从事中医呼吸相关研究,E-mail:thinker_2016@163.com。
